title: Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.
abstract: Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB malignancies will be presented, including indications and potential pitfalls.
authors.affiliation: Department of Surgery, Clinical Sciences Lund, Lund University, Lund, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Ansari
authors.forename: Inger
authors.initials: I
authors.lastname: Keussen
authors.forename: Roland
authors.initials: R
authors.lastname: Andersson
mesh_terms: D001661:Biliary Tract Neoplasms / Q000000981:diagnostic imaging*; D005188:False Negative Reactions; D005189:False Positive Reactions; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging*; D064847:Multimodal Imaging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18